Insulet reported $3.17B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Abbott USD 110.43B 23.72B Mar/2026
Align Technology USD 6.42B 103.41M Jun/2026
AtriCure USD 676.64M 32.66M Jun/2026
Baxter International USD 19.79B 55M Jun/2026
Becton, Dickinson and Co. USD 50.73B 101M Jun/2026
Boston Scientific USD 45.22B 865M Jun/2026
Cardinal Health USD 57.3B 610M Jun/2026
Cooper Companies USD 12.48B 58.1M Mar/2026
Dexcom USD 6.46B 178M Jun/2026
Edwards Lifesciences USD 13.87B 545.9M Jun/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Globus Medical USD 5.49B 48.7M Jun/2026
ICU Medical USD 3.97B 42.48M Jun/2026
Inogen USD 307.01M 5.03M Sep/2025
Insulet USD 3.17B 177.9M Jun/2026
Integra LifeSciences USD 3.56B 14.24M Jun/2026
J&J USD 201.06B 167M Jun/2026
Medtronic USD 93.03B 1.54B Mar/2026
Merit Medical Systems USD 2.86B 144.34M Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Solventum Corp USD 14.24B 146M Jun/2026
Stryker USD 47.93B 1.64B Jun/2026
Tandem Diabetes Care USD 1.15B 808K Jun/2026
Teleflex USD 6.79B 3.78M Jun/2026
West Pharmaceutical Services USD 4.08B 33.4M Jun/2026
Zimmer Biomet Holdings USD 22.8B 76.2M Jun/2026